Copyright Reports & Markets. All rights reserved.

Global Peripheral Intervention Drug-Eluting Devices Market Report 2018-2029

Request for Sample of this report
Buy now

1 Industry Overview of Peripheral Intervention Drug-Eluting Devices

  • 1.1 Research Scope
  • 1.2 Market Segmentation by Types of Peripheral Intervention Drug-Eluting Devices
  • 1.3 Market Segmentation by End Users of Peripheral Intervention Drug-Eluting Devices
  • 1.4 Market Dynamics Analysis of Peripheral Intervention Drug-Eluting Devices
    • 1.4.1 Market Drivers
    • 1.4.2 Market Challenges
    • 1.4.3 Market Opportunities
    • 1.4.4 Porter’s Five Forces

2 Major Manufacturers Analysis of Peripheral Intervention Drug-Eluting Devices Industry

  • 2.1 Medtronic plc
    • 2.1.1 Company Overview
    • 2.1.2 Main Products and Specifications
    • 2.1.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.1.4 Contact Information
  • 2.2 Boston Scientific Corporation
    • 2.2.1 Company Overview
    • 2.2.2 Main Products and Specifications
    • 2.2.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.2.4 Contact Information
  • 2.3 Abbott Laboratories
    • 2.3.1 Company Overview
    • 2.3.2 Main Products and Specifications
    • 2.3.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.3.4 Contact Information
  • 2.4 Cardinal Health
    • 2.4.1 Company Overview
    • 2.4.2 Main Products and Specifications
    • 2.4.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.4.4 Contact Information
  • 2.5 B. Braun Melsungen AG
    • 2.5.1 Company Overview
    • 2.5.2 Main Products and Specifications
    • 2.5.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.5.4 Contact Information
  • 2.6 Biosensors International Group Ltd.
    • 2.6.1 Company Overview
    • 2.6.2 Main Products and Specifications
    • 2.6.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.6.4 Contact Information
  • 2.7 C.R. Bard, Inc.
    • 2.7.1 Company Overview
    • 2.7.2 Main Products and Specifications
    • 2.7.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.7.4 Contact Information
  • 2.8 St. Jude Medical, Inc.
    • 2.8.1 Company Overview
    • 2.8.2 Main Products and Specifications
    • 2.8.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.8.4 Contact Information
  • 2.9 The Lubrizol Corporation
    • 2.9.1 Company Overview
    • 2.9.2 Main Products and Specifications
    • 2.9.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.9.4 Contact Information
  • 2.10 Terumo Corporation
    • 2.10.1 Company Overview
    • 2.10.2 Main Products and Specifications
    • 2.10.3 Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Price and Gross Margin (2018-2023)
    • 2.10.4 Contact Information

3 Global Peripheral Intervention Drug-Eluting Devices Market Analysis by Regions, Manufacturers, Types and End Users

  • 3.1 Global Sales Volume and Revenue of Peripheral Intervention Drug-Eluting Devices by Regions (2018-2023)
  • 3.2 Global Sales Volume and Revenue of Peripheral Intervention Drug-Eluting Devices by Manufacturers (2018-2023)
  • 3.3 Global Sales Volume and Revenue of Peripheral Intervention Drug-Eluting Devices by Types (2018-2023)
  • 3.4 Global Sales Volume and Revenue of Peripheral Intervention Drug-Eluting Devices by End Users (2018-2023)
  • 3.5 Selling Price Analysis of Peripheral Intervention Drug-Eluting Devices by Regions, Manufacturers, Types and End Users in (2018-2023)

4 Northern America Peripheral Intervention Drug-Eluting Devices Market Analysis by Countries, Types and End Users

  • 4.1 Northern America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 4.2 Northern America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Types (2018-2023)
  • 4.3 Northern America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 4.4 United States Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 4.5 Canada Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)

5 Europe Peripheral Intervention Drug-Eluting Devices Market Analysis by Countries, Types and End Users

  • 5.1 Europe Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 5.2 Europe Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Types (2018-2023)
  • 5.3 Europe Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 5.4 Germany Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.5 France Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.6 UK Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.7 Italy Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.8 Russia Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.9 Spain Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 5.10 Netherlands Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)

6 Asia Pacific Peripheral Intervention Drug-Eluting Devices Market Analysis by Countries, Types and End Users

  • 6.1 Asia Pacific Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 6.2 Asia Pacific Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Types (2018-2023)
  • 6.3 Asia Pacific Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 6.4 China Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.5 Japan Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.6 Korea Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.7 India Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.8 Australia Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.9 Indonesia Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 6.10 Vietnam Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)

7 Latin America Peripheral Intervention Drug-Eluting Devices Market Analysis by Countries, Types and End Users

  • 7.1 Latin America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 7.2 Latin America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Types (2018-2023)
  • 7.3 Latin America Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 7.4 Brazil Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.5 Mexico Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.6 Argentina Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 7.7 Colombia Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)

8 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Market Analysis by Countries, Types and End Users

  • 8.1 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Countries (2018-2023)
  • 8.2 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by Types (2018-2023)
  • 8.3 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales Volume and Revenue Analysis by End Users (2018-2023)
  • 8.4 Turkey Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.5 Saudi Arabia Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.6 South Africa Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)
  • 8.7 Egypt Peripheral Intervention Drug-Eluting Devices Sales Volume, Revenue, Import and Export Analysis (2018-2023)

9 Marketing Channel, Distributors and Traders Analysis

  • 9.1 Marketing Channel
    • 9.1.1 Direct Channel
    • 9.1.2 Indirect Channel
  • 9.2 Distributors and Traders

10 Global Peripheral Intervention Drug-Eluting Devices Market Forecast by Regions, Countries, Manufacturers, Types and End Users

  • 10.1 Global Sales Volume and Revenue Forecast of Peripheral Intervention Drug-Eluting Devices by Regions (2024-2029)
  • 10.2 Global Sales Volume and Revenue Forecast of Peripheral Intervention Drug-Eluting Devices by Types (2024-2029)
  • 10.3 Global Sales Volume and Revenue Forecast of Peripheral Intervention Drug-Eluting Devices by End Users (2024-2029)
  • 10.4 Global Revenue Forecast of Peripheral Intervention Drug-Eluting Devices by Countries (2024-2029)
    • 10.4.1 United States Revenue Forecast (2024-2029)
    • 10.4.2 Canada Revenue Forecast (2024-2029)
    • 10.4.3 Germany Revenue Forecast (2024-2029)
    • 10.4.4 France Revenue Forecast (2024-2029)
    • 10.4.5 UK Revenue Forecast (2024-2029)
    • 10.4.6 Italy Revenue Forecast (2024-2029)
    • 10.4.7 Russia Revenue Forecast (2024-2029)
    • 10.4.8 Spain Revenue Forecast (2024-2029)
    • 10.4.9 Netherlands Revenue Forecast (2024-2029)
    • 10.4.10 China Revenue Forecast (2024-2029)
    • 10.4.11 Japan Revenue Forecast (2024-2029)
    • 10.4.12 Korea Revenue Forecast (2024-2029)
    • 10.4.13 India Revenue Forecast (2024-2029)
    • 10.4.14 Australia Revenue Forecast (2024-2029)
    • 10.4.15 Indonesia Revenue Forecast (2024-2029)
    • 10.4.16 Vietnam Revenue Forecast (2024-2029)
    • 10.4.17 Brazil Revenue Forecast (2024-2029)
    • 10.4.18 Mexico Revenue Forecast (2024-2029)
    • 10.4.19 Argentina Revenue Forecast (2024-2029)
    • 10.4.20 Colombia Revenue Forecast (2024-2029)
    • 10.4.21 Turkey Revenue Forecast (2024-2029)
    • 10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
    • 10.4.23 South Africa Revenue Forecast (2024-2029)
    • 10.4.24 Egypt Revenue Forecast (2024-2029)

11 Industry Chain Analysis of Peripheral Intervention Drug-Eluting Devices

  • 11.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Peripheral Intervention Drug-Eluting Devices
    • 11.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Peripheral Intervention Drug-Eluting Devices
    • 11.1.2 Major Equipment Suppliers with Contact Information Analysis of Peripheral Intervention Drug-Eluting Devices
  • 11.2 Downstream Major Consumers Analysis of Peripheral Intervention Drug-Eluting Devices
  • 11.3 Major Suppliers of Peripheral Intervention Drug-Eluting Devices with Contact Information
  • 11.4 Supply Chain Relationship Analysis of Peripheral Intervention Drug-Eluting Devices

12 Peripheral Intervention Drug-Eluting Devices New Project Investment Feasibility Analysis

  • 12.1 Peripheral Intervention Drug-Eluting Devices New Project SWOT Analysis
  • 12.2 Peripheral Intervention Drug-Eluting Devices New Project Investment Feasibility Analysis
    • 12.2.1 Project Name
    • 12.2.2 Investment Budget
    • 12.2.3 Project Product Solutions
    • 12.2.4 Project Schedule

13 Peripheral Intervention Drug-Eluting Devices Research Findings and Conclusion

    14 Appendix

    • 14.1 Research Methodology
    • 14.2 References and Data Sources
      • 14.2.1 Primary Sources
      • 14.2.2 Secondary Paid Sources
      • 14.2.3 Secondary Public Sources
    • 14.3 Abbreviations and Units of Measurement
    • 14.4 Author Details

    The Peripheral Intervention Drug-Eluting Devices industry plays a crucial role in improving patient outcomes through innovative medical solutions. This market analysis article aims to provide an overview of Peripheral Intervention Drug-Eluting Devices, their applications, current industry status, and future prospects. In 2022, the global Peripheral Intervention Drug-Eluting Devices market size was estimated at US$5796 million, with a projected compound annual growth rate (CAGR) of 7.8%.

    Definition and Applications:
    Peripheral Intervention Drug-Eluting Devices are advanced medical devices used primarily in Drug-Eluting Balloons (DEBs) and Drug-Eluting Stents (DES). These devices incorporate specialized pharmaceutical coatings that release therapeutic drugs gradually to prevent restenosis and promote healing. DEBs and DES are commonly employed in diverse peripheral interventions, including vascular, neurology, and oncology procedures.

    Industry Status:
    The Peripheral Intervention Drug-Eluting Devices industry is witnessing significant growth due to several factors. Firstly, the rising prevalence of diseases requiring peripheral interventions, such as peripheral artery disease and coronary artery disease, drives the demand for drug-eluting solutions. Additionally, the increasing adoption of minimally invasive procedures and advancements in drug-eluting technologies contribute to the industry's growth.

    Global manufacturers:
    The market is dominated by major global manufacturers who specialize in producing high-quality and effective Peripheral Intervention Drug-Eluting Devices. These manufacturers include:

    Medtronic plc: Medtronic is renowned for its comprehensive portfolio of drug-eluting devices, which contribute to managing multiple vascular conditions.
    Boston Scientific Corporation: Boston Scientific offers a wide range of innovative drug-eluting solutions, including DEBs and DES, known for their efficacy in peripheral interventions.
    Abbott Laboratories: Abbott Laboratories is a leading player in the Peripheral Intervention Drug-Eluting Devices market, particularly known for their DES platforms.
    Cardinal Health: Cardinal Health provides drug-eluting solutions designed to enhance patient outcomes and improve procedural efficacy.
    B. Braun Melsungen AG: B. Braun Melsungen offers drug-eluting technologies designed to address various peripheral intervention needs.
    Biosensors International Group Ltd.: Biosensors International focuses on developing cutting-edge drug-eluting solutions for improved patient care.
    C.R. Bard, Inc.: C.R. Bard specializes in drug-eluting technologies that cater to the specific requirements of peripheral interventions.
    St. Jude Medical, Inc.: St. Jude Medical offers a range of innovative drug-eluting devices, demonstrating its commitment to advancing peripheral intervention treatments.
    The Lubrizol Corporation: The Lubrizol Corporation is known for its drug-eluting coatings that enhance the performance and durability of peripheral intervention devices.
    Terumo Corporation: Terumo Corporation provides drug-eluting solutions that contribute to the successful treatment of various peripheral conditions.
    Future Prospects:
    The future prospects of the Peripheral Intervention Drug-Eluting Devices industry are promising. With an anticipated CAGR of 7.8% between 2022 and beyond, the market is expected to witness substantial growth. Factors contributing to this positive outlook include the growing aging population, increasing prevalence of peripheral artery diseases, and ongoing advancements in drug-eluting technologies. Additionally, the expansion of healthcare infrastructure in emerging markets presents untapped opportunities for market players to penetrate new geographical regions.

    Conclusion:
    The Peripheral Intervention Drug-Eluting Devices industry is a vital component of modern healthcare, providing innovative solutions for peripheral interventions. With a projected market size of US$5796 million in 2022 and a CAGR of 7.8%, the industry demonstrates strong growth potential. Major global manufacturers like Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cardinal Health, B. Braun Melsungen AG, and others are at the forefront of developing advanced drug-eluting technologies. As the demand for peripheral interventions increases, driven by aging populations and advancements in treatment options, the future of the Peripheral Intervention Drug-Eluting Devices industry appears promising.

    The SWOT analysis of the Peripheral Intervention Drug-Eluting Devices industry is as follows:

    Strengths:
    Efficacy in Preventing Restenosis: Peripheral Intervention Drug-Eluting Devices offer a significant advantage in preventing restenosis (re-narrowing of blood vessels) compared to non-drug-eluting devices, leading to improved patient outcomes.
    Technological Advancements: Continuous advancements in drug-eluting technologies enhance the precision, effectiveness, and durability of peripheral intervention devices, providing better treatment options for patients.
    Market Dominance of Key Players: Major global manufacturers such as Medtronic, Boston Scientific, and Abbott Laboratories hold significant market share, benefiting from established brand reputation, extensive product portfolios, and strong distribution networks.

    Weaknesses:
    High Development Costs: Developing and commercializing drug-eluting devices require substantial investments in research and development, regulatory approvals, and clinical trials, which can hinder smaller players from entering the market.
    Potential Side Effects: Despite their effectiveness, drug-eluting devices may carry the risk of adverse reactions to the drugs released, necessitating careful patient selection and monitoring.
    Limited Application Scope: Peripheral Intervention Drug-Eluting Devices are primarily used in specific peripheral interventions, such as vascular and neurology procedures, limiting their application in other medical specialties.

    Opportunities:
    Growing Aging Population: The increasing aging population worldwide is expected to drive the demand for peripheral interventions, creating opportunities for the growth of the Peripheral Intervention Drug-Eluting Devices industry.
    Emerging Markets: Expansion of healthcare infrastructure and rising disposable incomes in emerging markets provide untapped opportunities for market penetration and revenue growth.
    Technological Innovations: Ongoing advancements in drug-eluting technologies, including new coatings, drug formulations, and delivery systems, open doors for the development of more effective and targeted peripheral intervention devices.

    Threats:
    Regulatory Challenges: Strict regulations and lengthy approval processes imposed by regulatory bodies can delay product launches and increase compliance costs, posing challenges for manufacturers.
    Competition from Non-Drug-Eluting Devices: Non-drug-eluting devices, such as bare-metal stents and standard balloons, continue to be used in peripheral interventions, representing potential competition for drug-eluting devices.
    Economic Uncertainty: Economic fluctuations, healthcare reimbursement policies, and budget constraints may impact the adoption and affordability of drug-eluting devices, affecting market growth.

    Key players in global Peripheral Intervention Drug-Eluting Devices market include:
    Medtronic plc
    Boston Scientific Corporation
    Abbott Laboratories
    Cardinal Health
    B. Braun Melsungen AG
    Biosensors International Group Ltd.
    C.R. Bard, Inc.
    St. Jude Medical, Inc.
    The Lubrizol Corporation
    Terumo Corporation

    Market segmentation, by product types:
    Plain Old Balloon Angioplasty (POBA)
    Percutaneous Transluminal Angioplasty (PTA)

    Market segmentation, by applications:
    Drug-Eluting Balloons
    Drug-Eluting Stents
    Buy now